OPKO Health, Inc. (OPK) stock

OPKNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3020% below fair value

$1.68+0.01 (+0.60%)

Close on Nov 13, 2026Market cap $1.25BP/E –Yield –

OPKO Health EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

OPKO Health's EV/EBITDA was 16.6× on Apr 29, 2022, against 17.9× a year earlier.

Period	Period end	Value	Change (pts)
2022	Apr 29, 2022	16.6×	+2.5
2021	Dec 31, 2021	14.0×	−58.5
2017	Jan 31, 2017	72.6×	−5.2
2016	Dec 30, 2016	77.8×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is OPK.

Revenue growth-8.3% · median 21.3%

Gross margin56.6% · median 81.1%

Operating margin-17.5% · median -2.9%

Net margin-29.5% · median -18.1%

Advertisement
300 × 250

See a number that looks wrong?